An expert panel was convened to consider new evidence that might prompt changes to clinical practices that were established with the 2010 Guideline Recommendations for Immunohistochemical (IHC) Testing of Estrogen and Progesterone Receptors (ER/PgR) in Breast Cancer.
During the open comment period, April15-29, 2019, the panel collected feedback on the draft recommendations from stakeholders. Expected for release later this year, the 2019 “Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Update” will include reaffirmations and updated recommendations.
American Society of Clinical Oncology
Kimberly Allison, MD, FCAP, Co-Chair
Antonio Wolff, MD, FASCO, Co-Chair
Elizabeth Hammond, MD, FCAP
Mitchell Dowsett, PhD
Lisa McShane, PhD
Lisa Carey, MD
Patrick L. Fitzgibbons, MD, FCAP
Daniel Hayes, MD
Sunil Lakhani, MD, MBA
Jane Perlmutter, PhD, MBA
Chuck Perou, PhD
Meredith Regan, ScD
David Rimm, MD, PhD, FCAP
Fraser Symmans, MD
Emina Emilia Torlakovic, MD, PhD, FCAP
Leticia Varella, MD
Giuseppe Viale, MD
Mariana Chavez Mac Gregor, MD, MS
Guideline status: Complete Recommendations
Published online ahead of print: April 19, 2010
Originally published: June 2010
Accreditation Requirements and Proficiency Testing (PT)
Accreditation checklist requirements regarding ER/PgR assay validation, specimen fixation, and proficiency testing are available to CAP accredited laboratories through e-LAB Solutions Suite or can be purchased by non-CAP accredited laboratories.
Meet PT requirements by ordering the appropriate program. Call the CAP customer contact center at 1-800-323-4040 option 1#.
Gain the practical skills, tools, and techniques needed to ensure testing accuracy as well as compliance with ASCO-CAP Guidelines for HER2 and ER/PgR testing.
Review more upcoming CAP evidence-based guidelines by the Pathology and Laboratory Quality Center for Evidence-based Guidelines.